Systemic β-blockade with once daily betimol(TM) or timoptic-XE(TM)

Journal of Ocular Pharmacology and Therapeutics

Volumn 15, Issue 3, 1999, Pages 225-231

  Stewart, William C ^a,b   Cate, Elin A ^a   Stewart, Jeanette A ^a  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOTEARS; TIMOLOL; TIMOLOL MALEATE;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EXERCISE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR PRESSURE; NORMAL HUMAN; PATIENT COMPLIANCE; SYSTOLIC BLOOD PRESSURE;

EID: 0033022430     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1999.15.225     Document Type: Article

References (18)

1. -. A multi-dose, double-masked, parallel, active-treatment-controlled, multi-clinic study of 0.5% Timoptic-XE and 0.5% Timoptic in patients with elevated intraocular pressure (IOP). Merck & Co., Inc. Internal Report DA-TIMXE10., 1995.
2. Laurence, J., Holder, D., Vogel, R., Gross, R.L., Haik, B.C., Karp, D.W., Koby, M.M., and Zimmerman T.J. A double-masked, placebo-controlled evaluation of timolol in a gel vehicle. J. Glaucoma, 2:177-182, 1993.
3. Hommer, A., Nowak, A., and Huber-Spitzy, V. Multicenter double-blind study with 0.25% timolol in Gelrite (TG) once daily vs. 0.25% timolol solution (TS) twice daily. Ophthalmologe, 92:546-549, 1995.
4. Mantziris, D.A., Konstas, A.G.P., Maltezos, A., and Stewart, W.C. Diurnal variation of intraocular pressure in exfoliation or primary open-angle glaucoma patients treated with timolol 0.5% and timolol gel forming ophthalmic solution. Invest. Ophthalmol. Vis. Sci., 38(suppl):S2593, 1997.
5. Stewart, W.C., Leland, T.M., Cate, E.A., and Stewart, J.A. Efficacy and safety of timolol solution once daily vs. Timolol gel in treating elevated IOP. J. Glaucoma, 7:402-407, 1998.
6. Stewart, W.C. New and current drug therapy for glaucoma. Ciba Clinical Symposium, Duluth, GA, 1997, pp. 1-47.
7. Cantor, L.B., Alvi, N.P., Hoop, J.S., Katz, L.J., Flartey, K., and Brizendine, E.J. Comparison of once daily levobunolol 0.5% versus timolol XE 0.5% for the control of intraocular pressure and patient comfort. Invest. Ophthalmol. Vis. Sci., 38(suppl):S558, 1997.
8. Johnsson, G. and Regårdh, C.-G. Clinical pharmacokinetics of ß-adrenoreceptor blocking drugs. Clin. Pharmacokinetics, 1:233-263, 1976.
9. Dickstein, K. and Aarsland, T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am. J. Ophthalmol., 121:367-371, 1996.
10. Stuart, R.J. and Ellstad, M.J. National survey of exercise stress testing facilities. Chest, 77:94-97, 1980.
11. Rosner, B. Fundamentals of Biostatistics, Duxbury Press, Boston, 1982, pp. 410-447.
12. Book, S.A. Essentials of Statistics, McGraw Hill Book Company, New York, 1978, pp. 117-122, 205-215.
13. Shedden, A.H. Timolol maleate in gel-forming solution: A novel formulation of timolol maleate, Chilbret Int. J. Ophthalmol., 10:32-36, 1994.
14. Zimmerman, T.J. and Kaufman, H.E. Timolol: A β-adrenergic blocking agent for the treatment of glaucoma. Arch. Ophthalmol., 95:601, 1977.
15. Stewart, W.C. and Castelli, W.P. Systemic side effects of topical β-adrenergic blockers. Clin. Cardiol., 19:691-697, 1996.
16. Stewart, W.C., Sine, C., Cate, E., Minno, G.E., and Hunt, H.H. Daily cost of ß-adrenergic blocker therapy. Arch. Ophthalmol., 115:853-856, 1997.
17. Åblad, B., Ervik, M., Hallgren, J., Johnsson, G., and Sölvell, L. Pharmacological effects and serum levels of orally administered alprenolol in man. Europ. J. Clin. Pharmacol., 5:44-52, 1972.
18. Pine, M., Favrot, L., Smith, S., McDonald, K., and Chidsey, C.A. Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris. Circulation, 52:886-893, 1975.